Intra-Cellular Therapies Inc (ITCI)
72.66
+0.86
(+1.19%)
USD |
NASDAQ |
May 01, 16:00
72.74
+0.08
(+0.10%)
Pre-Market: 20:00
Intra-Cellular Therapies Free Cash Flow: -124.47M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -124.47M |
| September 30, 2023 | -161.57M |
| June 30, 2023 | -189.50M |
| March 31, 2023 | -247.62M |
| December 31, 2022 | -270.96M |
| September 30, 2022 | -304.98M |
| June 30, 2022 | -331.09M |
| March 31, 2022 | -295.52M |
| December 31, 2021 | -259.87M |
| September 30, 2021 | -255.00M |
| June 30, 2021 | -239.17M |
| March 31, 2021 | -226.86M |
| December 31, 2020 | -230.34M |
| September 30, 2020 | -196.43M |
| June 30, 2020 | -162.89M |
| March 31, 2020 | -144.24M |
| December 31, 2019 | -128.68M |
| September 30, 2019 | -123.50M |
| June 30, 2019 | -121.71M |
| Date | Value |
|---|---|
| March 31, 2019 | -126.98M |
| December 31, 2018 | -118.56M |
| September 30, 2018 | -114.65M |
| June 30, 2018 | -100.74M |
| March 31, 2018 | -92.07M |
| December 31, 2017 | -81.22M |
| September 30, 2017 | -84.36M |
| June 30, 2017 | -99.51M |
| March 31, 2017 | -88.08M |
| December 31, 2016 | -91.31M |
| September 30, 2016 | -97.95M |
| June 30, 2016 | -88.90M |
| March 31, 2016 | -106.57M |
| December 31, 2015 | -103.14M |
| September 30, 2015 | -74.26M |
| June 30, 2015 | -58.06M |
| March 31, 2015 | -32.06M |
| December 31, 2014 | -22.82M |
| September 30, 2014 | -16.61M |
Free Cash Flow Range, Past 5 Years
-331.09M
Minimum
Jun 2022
-121.71M
Maximum
Jun 2019
-211.28M
Average
-226.86M
Median
Mar 2021
Free Cash Flow Benchmarks
| Johnson & Johnson | 18.23B |
| Insmed Inc | -549.54M |
| Vertex Pharmaceuticals Inc | 3.279B |
| Fate Therapeutics Inc | -138.42M |
| ADMA Biologics Inc | 3.819M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.061M |
| Cash from Investing (Quarterly) | 47.42M |
| Cash from Financing (Quarterly) | 3.004M |
| Free Cash Flow Per Share (Quarterly) | -0.0214 |
| Free Cash Flow to Equity (Quarterly) | -2.062M |
| Free Cash Flow to Firm (Quarterly) | -2.062M |
| Free Cash Flow Yield | -1.79% |